3187-27-7

Basic information

• Product Name: cyclohexane-1,1-diethanol
• Synonyms: cyclohexane-1,1-diethanol;1,1-Cyclohexanediethanol;2,2'-(cyclohexane-1,1-diyl)diethanol
• CAS NO: 3187-27-7
• Molecular Formula: C₁₀H₂₀O₂
• Molecular Weight: 172.2646
• EINECS: 221-684-9
• Mol File: 3187-27-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 281.9°Cat760mmHg
• Flash Point: 129.7°C
• Appearance: /
• Density: 0.984g/cm³
• Vapor Pressure: 0.000409mmHg at 25°C
• Refractive Index: 1.475
• PKA: 14.84±0.10(Predicted)
• CAS DataBase Reference: cyclohexane-1,1-diethanol(CAS DataBase Reference)
• NIST Chemistry Reference: cyclohexane-1,1-diethanol(3187-27-7)
• EPA Substance Registry System: cyclohexane-1,1-diethanol(3187-27-7)

Safety Data

• Hazardous Substances Data: 3187-27-7(Hazardous Substances Data)

Usage

General Description

Cyclohexane-1,1-diethanol is a chemical compound with the molecular formula C10H20O2. It is a colorless, odorless liquid that is used primarily as a solvent in various industrial applications. The diol functionality in cyclohexane-1,1-diethanol makes it a useful ingredient in the production of polymers, resins, and plastics. It is also used as a surfactant and emulsifier in the formulation of personal care products, such as shampoos and lotions. Additionally, it can be used as a precursor in the synthesis of other organic compounds. Overall, cyclohexane-1,1-diethanol is a versatile chemical with a wide range of industrial and commercial applications.

InChI:InChI=1/C10H20O2/c11-8-6-10(7-9-12)4-2-1-3-5-10/h11-12H,1-9H2

Upstream product

• 4355-11-7 1,1-cyclohexanediacetic acid 
• 4355-15-1 2,4-dioxo-3-azaspiro[5.5]undecane-1,5-dicarbonitrile 
• 70197-61-4 Dimethyl 1,1-cyclohexanediacetate 
• 108667-25-0 cyclohexylidenedi-acetic acid diethyl ester 

Downstream Products

• 57740-28-0 1,1-bis-[2-(toluene-4-sulfonyloxy)-ethyl]-cyclohexane 
• 4375-49-9 3-benzyl-3-azaspiro[5.5]undecane 
• 6051-08-7 3-oxaspiro[5.5]undecan-2-one 
• 518285-18-2 2-[1-[2-(tert-Butyldiphenylsiloxy)ethyl]cyclohexyl]ethanol 
• 518285-27-3 2-[1-(2-Benzyloxyethyl)cyclohexyl]ethanol 
• 102760-07-6 1,1-bis-[2-(4-nitro-phenoxy)-ethyl]-cyclohexane 
• 114722-07-5 1,1-bis-[2-(4-amino-phenoxy)-ethyl]-cyclohexane 
• 17065-15-5 1,1-Divinylcyclohexan 
• 891829-37-1 (E)-4-[1-((E)-3-Ethoxycarbonyl-allyl)-cyclohexyl]-but-2-enoic acid ethyl ester 
• 127747-07-3 1,1-di(2-methanesulfonyloxyethyl)cyclohexane 
• 70197-51-2 [1-(2-oxo-ethyl)-cyclohexyl]-acetaldehyde 
• 3187-34-6 1,1-bis-(2-bromo-ethyl)-cyclohexane 
• 180-45-0 3-oxa-spiro[5.5]undecane 

Relevant articles and documents

A phosphine-free iron complex-catalyzed synthesis of cycloalkanes: Via the borrowing hydrogen strategy

Herein we report a diaminocyclopentadienone iron tricarbonyl complex catalyzed synthesis of substituted cyclopentane, cyclohexane and cycloheptane compounds using the borrowing hydrogen strategy in the presence of various substituted primary and secondary 1,n diols as alkylating reagents. Deuterium labeling experiments confirm that the diols were the hydride source in this cascade process. This journal is

Stereoselective Synthesis of Cyclohexanes via an Iridium Catalyzed (5 + 1) Annulation Strategy

An iridium catalyzed method for the synthesis of functionalized cyclohexanes from methyl ketones and 1,5-diols is described. This process operates by two sequential hydrogen borrowing reactions, providing direct access to multisubstituted cyclic products with high levels of stereocontrol. This methodology represents a novel (5 + 1) strategy for the stereoselective construction of the cyclohexane core.

SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF

The present invention relates to a CXCR3 antagonist comprising a compound represented by formula (I) (wherein all the symbols have the same meaning as defined in the description), a salt thereof, a quaternary ammonium salt thereof, an N-oxide form thereof or a solvate thereof, or a prodrug thereof. This antagonist is useful as a preventive, therapeutic and/or progression-suppressing agent for a CXCR3-mediated disease such as an immune or an allergic disease [e.g., an atopic disease, an autoimmune disease (e.g., multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, glomerulonephritis, Sjogren's syndrome and the like), systemic inflammatory response syndrome (SIRS), a rejection response to transplanted organ, tissue and/or cell or the like], a gastrointestinal disease [e.g., an inflammatory bowel disease or the like], or a respiratory disease [e.g., asthma, a chronic obstructive pulmonary disease or the like].